Lilliputian

Lilliputian Medicines is a precision oncology company focused on developing next-generation small molecule therapeutics for historically "undruggable" targets. The company leverages a proprietary discovery platform to identify novel binding pockets and modulate complex protein-protein interactions, with a primary emphasis on the RAS signaling pathway. Their pipeline is centered on highly selective inhibitors for specific KRAS mutations, including G12D and G12V, which are prevalent in various solid tumors. Founded by industry veterans with deep expertise in drug discovery, Lilliputian aims to overcome the limitations of first-generation inhibitors to provide more durable clinical responses. The company is backed by prominent life science investors and operates out of the Cambridge biotech hub.